TMCnet News

iOnctura Boosts Management Team With Appointment of David Seeberger as VP Finance
[August 04, 2021]

iOnctura Boosts Management Team With Appointment of David Seeberger as VP Finance


GENEVA, Switzerland, Aug. 04, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, today announces the appointment of David Seeberger as Vice-president, Finance.

David Seeberger has extensive experience in publicly-listed growth-oriented biotech and medtech companies. Before taking charge of global finance operations at iOnctura, he served as VP Head of Finance Europe at NASDAQ listed bluebird bio, and held senior financial positions at Aegerion Pharmaceuticals, InterMune Corporation and Stryker Corporation.

“David has joined iOnctura at an exciting and expansive time in the company’s development,” said Catherine Pickering, CEO of iOnctura. “As our clinical programs and commercial ambitions step through the gears, his appreciation of the wider strategic life sciences landscape and proven track record in driving early businesses forward will be invaluable.”

Contacts
iOnctura
Catherine Pickering
Chief Executive Officer
T: +41 79 952 72 52
E: c.pickering@iOnctura.com



Press Relations
Jeremy Nieckowski
LifeSci Advisors
T: +41 79 699 97 27
E: jnieckowski@lifesciadvisors.com

iOnctura SA is a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface. iOnctura’s best-in-class drug development programs combine immune-mediated and direct anti-tumor activity to deliver molecules with superior clinical efficacy and safety in oncology. Its lead program, IOA-244, is the only semi-allosteric PI3Kdelta specific, orally dosed, small molecule inhibitor that is being developed in solid and hematological tumors to address tumor and stroma induced immune suppression. IOA-244 is currently in Phase 1b studies for solid and hematological tumors. iOnctura’s second program, IOA-289, is an oral small molecule that inhibits the cross-talk between the tumor and its stroma and is in a Phase 1 clinical study. iOnctura is backed by blue chip investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. For more information, please visit www.ionctura.com.


A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6f7e989b-acd6-41de-9403-02845730cc73


Primary Logo


[ Back To TMCnet.com's Homepage ]